Sindroxocin 2 mg/ml (IV Infusion)
10 mg vial: ৳ 908.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Doxorubicin hydrochloride |
| Company | Bots pvt limited |
Title and Categories
- Sindroxocin (Doxorubicin HCl) Injection
- Chemotherapy Medicine
- Cytotoxic Chemotherapy
Indications
- Adjuvant chemotherapy for axillary lymph node involvement in breast cancer
- Treatment of acute lymphoblastic leukemia
- Treatment of acute myeloblastic leukemia
- Treatment of Hodgkin lymphoma
- Treatment of Non-Hodgkin lymphoma
- Treatment of metastatic breast cancer
- Treatment of metastatic Wilms' tumor
- Treatment of metastatic neuroblastoma
- Treatment of metastatic soft tissue sarcoma
- Treatment of metastatic bone sarcomas
- Treatment of metastatic ovarian carcinoma
- Treatment of metastatic transitional cell bladder carcinoma
- Treatment of metastatic thyroid carcinoma
- Treatment of metastatic gastric carcinoma
- Treatment of metastatic bronchogenic carcinoma
Pharmacology
- Cytotoxic anthracycline topoisomerase II inhibitor
- Nucleotide base intercalation
- Cell membrane lipid binding activities
- Inhibition of nucleotide replication
- Inhibition of DNA and RNA polymerases
- Formation of DNA-cleavable complexes
Dosage and Administration
- Single agent dosage: 60 to 75 mg/m2 every 21 days intravenously
- Combination therapy dosage: 40 to 75 mg/m2 every 21 to 28 days intravenously
- Administration through central intravenous line
- Intravenous injection over 3 to 10 minutes
- Intravenous infusion through a central catheter
- Management of suspected extravasation
- Incompatibility with other drugs
Interaction
- Substrate of cytochrome P450 CYP3A4 and CYP2D6
- Substrate of P-glycoprotein (P-gp)
- Concurrent use with inhibitors and inducers of CYP3A4, CYP2D6, or P-gp
- Concurrent use with Trastuzumab
- Concurrent use with Paclitaxel
Contraindications
- Severe myocardial insufficiency
- Recent myocardial infarction
- Severe persistent drug-induced myelosuppression
- Severe hepatic impairment
- Severe hypersensitivity reaction
Side Effects
- Alopecia
- Nausea and vomiting
- Cardiomyopathy and arrhythmias
- Secondary malignancies
- Extravasation and tissue necrosis
- Severe myelosuppression
- Tumor lysis syndrome
- Radiation sensitization and recall
Pregnancy and Lactation
- Pregnancy Category D
- Potential fetal harm
- Need for effective contraception during treatment
- Excretion in human milk
- Serious adverse reactions in nursing infants
Special Populations
- Risk of late cardiovascular dysfunction in pediatric patients
- Long-term periodic cardiovascular monitoring for pediatric patients
- No overall differences in safety and effectiveness in geriatric patients
- Reduced clearance in patients with elevated serum bilirubin levels
Overdose Effects
- Extension of pharmacological action
- Fatal in high doses
- Acute myocardial degeneration
- Severe myelosuppression
- Delayed cardiac failure
Reconstitution
- Preparation with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP
- Protection from light during preparation and infusion
- Visual inspection prior to administration
- Caution in handling to minimize dermal exposure
Storage Conditions
- Dry storage at 2°C-8°C
- Protection from light
- No freezing
- Keep out of the reach of children